Janus Henderson Group PLC Raises Stake in STAAR Surgical (NASDAQ:STAA)

Janus Henderson Group PLC increased its position in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 25.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 221,141 shares of the medical instruments supplier's stock after purchasing an additional 44,330 shares during the period. Janus Henderson Group PLC owned 0.45% of STAAR Surgical worth $5,372,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Graham Capital Management L.P. lifted its position in STAAR Surgical by 237.4% in the fourth quarter. Graham Capital Management L.P. now owns 44,804 shares of the medical instruments supplier's stock valued at $1,088,000 after acquiring an additional 31,524 shares during the last quarter. Deutsche Bank AG grew its stake in STAAR Surgical by 6.9% during the 4th quarter. Deutsche Bank AG now owns 45,193 shares of the medical instruments supplier's stock worth $1,098,000 after buying an additional 2,932 shares during the last quarter. Centiva Capital LP acquired a new position in STAAR Surgical during the fourth quarter worth approximately $543,000. Broadwood Capital Inc. lifted its stake in STAAR Surgical by 0.7% in the fourth quarter. Broadwood Capital Inc. now owns 10,848,631 shares of the medical instruments supplier's stock valued at $263,513,000 after buying an additional 80,200 shares during the last quarter. Finally, Bridgefront Capital LLC lifted its stake in STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock valued at $262,000 after buying an additional 2,306 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company's stock.

Insider Buying and Selling at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. bought 8,200 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was bought at an average cost of $15.08 per share, with a total value of $123,656.00. Following the completion of the acquisition, the insider now owns 13,518,591 shares in the company, valued at approximately $203,860,352.28. This represents a 0.06% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders acquired 1,446,433 shares of company stock valued at $23,957,807. 1.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on STAA. Jefferies Financial Group downgraded shares of STAAR Surgical from a "buy" rating to a "hold" rating in a research report on Wednesday, February 12th. Canaccord Genuity Group upped their target price on shares of STAAR Surgical from $17.00 to $20.00 and gave the company a "hold" rating in a report on Thursday, May 8th. Needham & Company LLC reissued a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. Stifel Nicolaus dropped their price target on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th. Finally, StockNews.com downgraded STAAR Surgical from a "hold" rating to a "sell" rating in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $24.63.

STAAR Surgical Price Performance

STAAR Surgical stock opened at $19.22 on Monday. The stock's 50 day moving average price is $17.60 and its 200 day moving average price is $21.47. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $49.86. The company has a market cap of $951.89 million, a PE ratio of -46.88 and a beta of 0.65.

STAAR Surgical announced that its board has authorized a share repurchase program on Friday, May 16th that permits the company to repurchase $30.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 3.2% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's board of directors believes its stock is undervalued.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.